scholarly journals Simeprevir plus sofosbuvir (12 and 8 weeks) in hepatitis C virus genotype 1-infected patients without cirrhosis: OPTIMIST-1, a phase 3, randomized study

Hepatology ◽  
2016 ◽  
Vol 64 (2) ◽  
pp. 370-380 ◽  
Author(s):  
Paul Kwo ◽  
Norman Gitlin ◽  
Ronald Nahass ◽  
David Bernstein ◽  
Kyle Etzkorn ◽  
...  
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Randomized Study ◽  
Genotype 1 ◽  
Virus Genotype ◽  
Phase 3

scholarly journals Simeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cirrhosis: A phase 3 study (OPTIMIST-2)

Hepatology ◽  
2016 ◽  
Vol 64 (2) ◽  
pp. 360-369 ◽  
Author(s):  
Eric Lawitz ◽  
Gary Matusow ◽  
Edwin DeJesus ◽  
Eric M. Yoshida ◽  
Franco Felizarta ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Genotype 1 ◽  
Virus Genotype ◽  
Phase 3 ◽  
Chronic Hepatitis C Virus

scholarly journals Vaniprevir plus peginterferon alfa‐2b and ribavirin in treatment‐experienced Japanese patients with hepatitis C virus genotype 1 (GT1b) infection: Phase 3 studies

2016 ◽  
Vol 31 (10) ◽  
pp. 1674-1683 ◽  
Author(s):  
Hiromitsu Kumada ◽  
Satoshi Mochida ◽  
Fumitaka Suzuki ◽  
Kazuaki Chayama ◽  
Yoshiyasu Karino ◽  
...  
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Japanese Patients ◽  
Genotype 1 ◽  
Virus Genotype ◽  
Phase 3 ◽  
Peginterferon Alfa
Sign in / Sign up

Export Citation Format

Share Document